Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

AlloVir Yönetim

Yönetim kriter kontrolleri 3/4

AlloVir's CEO'su Diana Brainard, May2021 tarihinde atandı, in görev süresi 3.42 yıldır. in toplam yıllık tazminatı $ 6.06M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10.3% maaş ve 89.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.28% ine doğrudan sahiptir ve bu hisseler $ 260.37K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.8 yıl ve 4.3 yıldır.

Anahtar bilgiler

Diana Brainard

İcra Kurulu Başkanı

US$6.1m

Toplam tazminat

CEO maaş yüzdesi	10.3%
CEO görev süresi	3.4yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	5.8yrs
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Mar 21

AlloVir: A Comparative Study Of Its Manufacturing Process

Feb 07

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Nov 02

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Oct 02

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 06

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Jul 01

AlloVir EPS misses by $0.08

May 06

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Apr 01

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Feb 07

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

Jan 08

FDA clears AlloVir's ALVR106 application in respiratory viruses

Dec 17

Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

Dec 07

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Dec 04

AlloVir EPS misses by $0.28

Nov 10

CEO Tazminat Analizi

Diana Brainard'un ücretlendirmesi AlloVir'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$140m
Mar 31 2024	n/a	n/a	-US$180m
Dec 31 2023	US$6m	US$623k	-US$190m
Sep 30 2023	n/a	n/a	-US$169m
Jun 30 2023	n/a	n/a	-US$167m
Mar 31 2023	n/a	n/a	-US$166m
Dec 31 2022	US$9m	US$605k	-US$169m
Sep 30 2022	n/a	n/a	-US$189m
Jun 30 2022	n/a	n/a	-US$192m
Mar 31 2022	n/a	n/a	-US$185m
Dec 31 2021	US$15m	US$365k	-US$172m
Sep 30 2021	n/a	n/a	-US$139m
Jun 30 2021	n/a	n/a	-US$117m
Mar 31 2021	n/a	n/a	-US$91m
Dec 31 2020	US$597k	n/a	-US$70m

Tazminat ve Piyasa: Diana 'nin toplam tazminatı ($USD 6.06M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 677.23K ).

Tazminat ve Kazançlar: Diana 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Diana Brainard (52 yo)

3.4yrs

Görev süresi

US$6,056,943

Tazminat

Dr. Diana M. Brainard, MD., served as an Entrepreneur Partner at MPM Asset Management, L.L.C. since 2024. She served as an Executive Partner and Entrepreneur at MPM Asset Management, L.L.C. till December 2...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Hallal	Executive Chairman of the Board	6.1yrs	US$347.00k	2.46% $ 2.2m
Diana Brainard	CEO & Director	3.4yrs	US$6.06m	0.28% $ 253.0k
Vikas Sinha	President	5.8yrs	US$2.94m	0.85% $ 757.8k
Edward Miller	General Counsel & Secretary	5.8yrs	US$1.89m	0.37% $ 332.6k
Brett Hagen	Chief Accounting Officer	5.8yrs	Veri yok	0.063% $ 56.5k
Ann Leen	Chief Scientific Officer	11.8yrs	Veri yok	2.02% $ 1.8m
Cintia Piccina	Chief Commercial Officer	1.3yrs	Veri yok	Veri yok

5.8yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: ALVR 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Hallal	Executive Chairman of the Board	6.1yrs	US$347.00k	2.46% $ 2.2m
Diana Brainard	CEO & Director	4.3yrs	US$6.06m	0.28% $ 253.0k
Vikas Sinha	President	5.8yrs	US$2.94m	0.85% $ 757.8k
John Mellors	Member of the Scientific Advisory Board	1.7yrs	Veri yok	Veri yok
Malcolm Brenner	Independent Non-Executive Director	12.8yrs	US$196.28k	0.20% $ 179.8k
Jeffrey Bornstein	Independent Non-Executive Director	4.3yrs	US$211.78k	0.066% $ 59.1k
Michael Boeckh	Member of Scientific Advisory Board	1.7yrs	Veri yok	Veri yok
John DiPersio	Member of Scientific Advisory Board	1.7yrs	Veri yok	Veri yok
Anil Chandraker	Member of Scientific Advisory Board	1.7yrs	Veri yok	Veri yok
Morana Jovan-Embiricos	Independent Non-Executive Director	5.4yrs	US$209.28k	8.67% $ 7.8m
Shawn Tomasello	Independent Director	2.6yrs	US$200.73k	0.031% $ 27.5k
Juan Vera	Non-Executive Director	10.8yrs	US$187.00k	2.08% $ 1.9m

4.3yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ALVR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

AlloVir Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

Allovir Announces Appointment of Cintia Piccina as Chief Commercial Officer

High number of new directors

CEO & Director notifies of intention to sell stock

Consultant notifies of intention to sell stock

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

Recent updates

Price target decreased by 20% to US$0.80

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

New major risk - Financial position

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Levi & Korsinsky, LLP Notifies Investors in Allovir, Inc. of a Class Action Securities Lawsuit

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Robbins LLP Announces Class Action File Against AlloVir, Inc

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Price target decreased by 71% to US$5.63

AlloVir, Inc. Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

New major risk - Share price stability

AlloVir, Inc. Presents Positive Final Results from A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of Bk Infection in Kidney Transplant Recipients At the American Transplant Congress

Allovir Announces Appointment of Cintia Piccina as Chief Commercial Officer

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

High number of new directors

Price target decreased by 7.6% to US$21.25

AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia

Price target decreased by 13% to US$23.00

CEO & Director notifies of intention to sell stock

AlloVir, Inc. Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023

AlloVir, Inc. Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study

Consultant notifies of intention to sell stock

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

General Counsel & Secretary notifies of intention to sell stock

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir, Inc. Announces That Final Data from the Phase 2 Study of Posoleuce

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board notifies of intention to sell stock

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board recently sold US$2.9m worth of stock

Chief Commercial Officer recently sold US$129k worth of stock

Price target decreased to US$27.50

AlloVir GAAP EPS of $0.69 beats by $1.42

AlloVir stock surges on $126.6M securities offering

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

AlloVir, Inc.(NasdaqGS:ALVR) dropped from Russell 2000 Growth Index

AlloVir, Inc. Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

Chief Commercial Officer recently sold US$67k worth of stock

Price target decreased to US$32.00

FDA Grants Regenerative Medicine Advanced Therapy to Allovir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

AlloVir, Inc., Annual General Meeting, May 17, 2022

AlloVir Announces Appointment of Shawn Tomasello to its Board of Directors

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Chief Commercial Officer recently sold US$128k worth of stock

AlloVir: A Comparative Study Of Its Manufacturing Process

Price target decreased to US$38.75

Insider notifies of intention to sell stock

President recently sold US$56k worth of stock

AlloVir, Inc. Announces U.S. Food and Drug Administration Grant Lead Multi-Virus Specific T Cell (VST) Therapy, Posoleucel (Viralym-M, ALVR105), Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Adenovirus (AdV) Infection

Price target decreased to US$42.75

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting

Chief Commercial Officer recently sold US$321k worth of stock

Chief Scientific Officer notifies of intention to sell stock

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

High number of new directors

Independent Non-Executive Director notifies of intention to sell stock

Insider recently sold US$447k worth of stock

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Insider notifies of intention to sell stock

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

AlloVir, Inc.(NasdaqGS:ALVR) dropped from Russell 3000E Value Index

Chief Scientific Officer recently sold US$3.4m worth of stock

AlloVir EPS misses by $0.08

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans